Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Medically reviewed by Marla Anderson, MDMultiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal ... Xu Feng, Ph.D., a professor in the UAB Department of Pathology’s Division of Molecular and Cellular Pathology, is ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Joseph Mikhael, MD, and Saad Usmani, MD, discuss treatment advances for transplant-ineligible multiple myeloma patients, highlighting recent advances in quadruplet regimens, frailty scoring ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.